​​​​​​More than 300,000 Canadians live with type 1 diabetes. A chronic and sometime fatal disease, type 1​ diabetes is an autoimmune disease that results in the destruction and elimination of insulin producing beta cells in the pancreas. The loss of beta cells ultimately leads to insulin dependence and major complications that are difficult to manage by insulin injections. Recent improvements in islet transplantations for the treatment of type 1 diabetes are increasing the likelihood of finding a possible cure for this disease. However, the requirement for 2–3 donors per transplantation, and the scarcity of donor pancreata, has launched the search for an alternative source of beta cells for cell therapy. Beta cells produced from human pluripotent stem cells (hPSCs) represent a new and potentially unlimited source of these cells for transplantation for the treatment of type 1 diabetes.

5 months in vitro maturation of hESC-derived pancreas progenitors  

Our Discoveries

  • A method to generate pancreatic progenitors from hPSCs.
  • A strategy to identify and purify hPSC-drived pancreatic progenitors and the demonstration that they can develop into insulin-producing beta cells.

Our Research

The focus of Dr. Cristina Nostro’s lab is to elucidate the signaling pathways governing the formation, expansion and maturation of pancreatic progenitors using human pluripotent stem cell directed differentiation. Through this in vitro approach we aim to understand the genetic and epigenetic program that dictates pancreatic development and beta cell maturation. Due to the very limited accessibility of the human embryo, this represents a powerful and unparalleled system to understand key human developmental processes. Furthermore, patient-specific iPSC directed differentiation will allow us to study disease development and progression in ways that were previously inconceivable.

In 2017, Dr. Nostro published a groundbreaking study in Nature Communications​ showing methods to effectively purify populations of pancreatic progenitor cells. These cells can successfully develop into insulin-producing beta-like cells enabling safer and more efficient testing of these cells across a larger nu​mber of laboratories, increasing the odds – and the speed – of changing the way we treat type 1 diabetes.